PDA Closure Rates and Safety after Repeated Courses of Cyclooxygenase Inhibitors in Preterm Infants: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis of 33 studies demonstrates that while cyclooxygenase inhibitors effectively treat patent ductus arteriosus in preterm infants, closure rates significantly decline with repeated courses (dropping from 62% after the first to 46% after the second and 38% after the third), and evidence regarding the safety of such repeated treatments remains limited.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the earliest weeks of life, a tiny blood vessel called the ductus arteriosus serves a vital purpose. Before birth, this vessel acts as a detour, allowing blood to bypass the lungs, which are filled with fluid and not yet ready to breathe air. Once a baby is born and takes that first breath, the lungs fill with air, and this vessel is supposed to close permanently, sealing off the detour. For most babies, this happens naturally within a few days. However, in many premature infants, the vessel remains open. This condition, known as a patent ductus arteriosus, forces blood to flow backward into the lungs, causing congestion and straining the heart and other organs.
To fix this, doctors often use medication to help the vessel close. The most common drugs are cyclooxygenase inhibitors, which work by blocking a specific chemical signal that keeps the vessel open. If the first round of medicine does not work, clinicians face a difficult choice: try the medication again, or move to surgery to tie off the vessel. While surgery carries its own risks, repeating the medicine is often seen as a gentler option. But a critical question has lingered in neonatal care: does giving the medicine a second or third time actually work, or does the body simply stop responding?
A team of researchers set out to answer this by gathering and analyzing data from dozens of studies conducted around the world. They looked at records from 33 different studies involving thousands of premature infants who had received one, two, or even three courses of this medication. Their goal was to see if the success rate of closing the vessel changed as the treatment was repeated. The findings reveal a clear and somewhat sobering pattern. When the medication is given for the first time, it successfully closes the vessel in about 62 out of every 100 babies. However, when a second course is administered to those whose vessels remained open, the success rate drops to 46 out of 100. If a third course is needed, the likelihood of success falls even further, to just 38 out of 100.
The researchers found that this decline in effectiveness was consistent across different groups of babies, including those born extremely early or with very low birth weights. It also held true regardless of whether the drug was ibuprofen or indomethacin, and whether it was given through a vein or by mouth, with one notable exception. When the medication was given orally, the drop in effectiveness after the second dose was not statistically significant, suggesting that the method of delivery might play a role in how the body responds to repeated treatment. The study also noted that while the medication becomes less effective with each attempt, the data on safety for these repeated doses is very limited. Only a handful of studies reported on side effects like kidney issues or bleeding, making it difficult to draw firm conclusions about the risks of giving the drug multiple times.
Ultimately, the study suggests that while a second or third round of medication is sometimes attempted, the chances of it working are significantly lower than the first attempt. The authors emphasize that this does not mean these treatments should never be used, but rather that doctors and parents should be aware that the odds of success decrease with each repetition. The evidence points to a need for more research, particularly regarding the safety of repeated doses and the best timing for intervention. For now, the data provides a clearer picture of what to expect: the first try is the most likely to succeed, and the window for closing the vessel with medicine narrows with every subsequent attempt.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.